Medical Device Commercial Strategy: Models for Growth
Medical device companies compete on products and are judged on revenue, and the mechanism connecting the two is decided long before a sales target is set. It is the commercial model: whether the device is sold outright, sold cheaply against a proprietary consumable, wrapped in a service agreement, rented as a subscription, or paid for only when it produces an agreed result. Most organisations inherit that choice rather than making it, and then spend years optimising inside a model that no longer fits the buyers they are selling to.
That last point is the subject of this article. Five commercial models are available — outright capital sale, capital plus consumables, capital plus service, device as a service, and outcome-based contracting — and choosing between them sets cash profile, sales structure and evidence burden simultaneously. They are not a maturity ladder. Moving from a capital sale to a subscription is not progress; it is a different business with different working capital needs.
This guide compares the five honestly, including the evidence that supports them. Device-as-a-service and outcome-based contracting attract most of the attention and rest on a smaller published base than the enthusiasm suggests. It also covers how value analysis committees actually buy, the arithmetic behind the rep-less debate, and the regulatory calendar that now determines which SKUs are worth keeping at all.
Why device commercial strategy is not pharmaceutical commercial strategy
A great deal of medtech commercial planning is adapted from pharmaceutical playbooks, usually by people who came from pharma. The adaptation fails in four specific places, and each failure is structural rather than a matter of execution.
| Structural difference | In pharma | In medical devices | Commercial consequence |
|---|---|---|---|
| Who decides | A prescriber chooses, within a formulary | A value analysis committee decides for the institution — surgeons, nurses, supply chain and finance together | A clinical dossier answers one of four questions in the room. Total cost of ownership answers the others |
| What is sold | A molecule; the service around it is marketing | A product inseparable from a service — training, case support, stocking, sterilisation, sometimes presence in theatre | The service is part of the cost of goods, not the cost of selling, which is why the rep-less debate is more complicated than it looks |
| Regulatory cost per SKU | High per molecule, across few molecules | High per device class, across many SKUs — and rising under MDR and IVDR | Portfolio breadth becomes a liability. Rationalisation is now a commercial decision, not a supply chain one |
| How revenue arrives | Per prescription, continuously | Depends entirely on the model chosen — a single capital event, a consumable annuity, a subscription, or a payment contingent on outcome | The model choice determines cash flow, sales structure and evidence burden at once. It cannot be changed per deal |
The consequence most often missed
Because the service is inseparable from the product, a device company's commercial model and its operating model are the same decision.
A pharmaceutical company can change its channel mix without changing what it manufactures. A device company moving from a capital sale to a subscription changes who owns the asset, who maintains it, how revenue is recognised, how much working capital is tied up, and what its field organisation does all day.
That is why model changes in medtech fail at implementation rather than at strategy. The strategy is usually sound; the organisation was costed for the model it is leaving.
The five medical device commercial models
Set out with what each requires and what it does to the business, because the trade-offs are rarely stated plainly in material written to promote one of them.
| Model | How revenue arrives | What it requires | Where it fits best |
|---|---|---|---|
| 1. Capital sale | A single payment at purchase | A buyer with capital budget, and a procurement cycle you can time | Established categories with clear substitutes, and buyers whose capital budget is genuinely available |
| 2. Capital plus consumables | Lower initial price, recurring revenue from proprietary consumables | A genuinely proprietary consumable, and protection against third-party substitution | The strongest economics in the list where it is defensible — and it invites procurement to attack the consumable price |
| 3. Capital plus service contract | Purchase plus a maintained service and uptime agreement | Field service capability, spare parts logistics and uptime measurement | Complex equipment where downtime has a clear operational cost the buyer already feels |
| 4. Device as a service | Periodic subscription covering equipment, service, consumables and often software | Balance sheet capacity to own the asset, and a buyer whose operating budget is easier to access than capital | Buyers who are capital-constrained but not cash-constrained. Common in emerging markets and in mid-size private hospitals |
| 5. Outcome-based | Payment contingent on a clinical or economic result | Measurable outcomes, agreed data sources, and the balance sheet to absorb a miss | Categories where the outcome is unambiguous, measurable within a sensible period, and attributable to the device |
Two observations that the model-by-model literature tends to avoid. The models are not a maturity ladder — moving from a capital sale to a subscription is not progress, it is a different business with different working capital needs. And models three, four and five all convert a product company into a service company to some degree, which is a decision about what the organisation is, not merely how it prices.
Medical device as a service: what the evidence actually shows
This is the term with the growth narrative attached, and it deserves a careful answer rather than an enthusiastic one. Four contracting approaches are documented in the published literature, each with named examples.
| Approach | How it works | Documented examples | Stated barrier |
|---|---|---|---|
| Outcomes-based risk sharing | The product must meet specific, timed clinical targets to be eligible for full reimbursement; the manufacturer carries financial responsibility if it does not | Medtronic's TYRX antibacterial envelope, where the company reimburses hospitals for costs associated with device infections; Cardiva Medical's VASCADE, covering post-surgical complication costs when targets are missed | Limited real-world data at launch, and payer scepticism about added value over established alternatives |
| Risk sharing with mutual gains | Reduced pricing in exchange for a share of achieved savings, usually with renegotiation rights | Medtronic's MiniMed insulin pump agreement with Aetna, tying payment to target HbA1c levels and total cost of care reduction | Payer preference for simpler, traditional funding mechanisms |
| Coverage with evidence development | Reimbursement authorised for a limited period, contingent on the manufacturer collecting further safety and efficacy data for later review | TAVI in South Korea, re-evaluated every three years; Terumo's HeartSheet in Japan, granted eight-year conditional approval requiring comparative studies | Difficulty collecting and using real-world data within existing health systems |
| Value-based procurement | The agreement covers outcome delivery including technical support and remote monitoring, rather than a device transaction | Medtronic's Catalonia ICD programme, reporting roughly 10% reductions in outpatient visits and implant complications within a €10 million four-year budget | Traditional procurement frameworks that cannot accommodate service integration |
The honest reading, which is more useful than the enthusiastic one
These models are real, documented and rare. Notice what the evidence base looks like when assembled: a small number of named programmes, a striking concentration in one manufacturer's portfolio, and a flagship value-based procurement result from a programme that began in 2016 and is still among the most-cited examples available.
That is not an argument against the models. It is an argument about what stage they are at. A category with a decade-old flagship case is not a category in rapid adoption, whatever the conference agenda suggests.
The binding constraint is procurement, not appetite. Every source lists the same barrier: hospital and payer purchasing frameworks are built to buy products at prices, and cannot easily buy outcomes over periods. A commercial team proposing an outcome-based model should test whether the buyer's procurement process can execute one before designing around it — that question is answerable in one meeting and saves a year.
How devices are actually bought: the value analysis committee
If the committee is the decision point, then understanding how it works is worth more than any amount of clinical advocacy — because clinical advocacy is one input into a process with several.
| Who is in the room | What they are assessing | What convinces them | What does not |
|---|---|---|---|
| Clinicians — surgeons, physicians | Clinical efficacy, safety, and whether the product changes what they can do | Comparative clinical evidence, and peer experience in similar institutions | Volume of published material unrelated to their case mix |
| Nursing and theatre staff | Workflow, training burden, whether it works under real conditions | Realistic implementation and training plans, and honesty about the learning curve | Claims that a new device requires no adaptation |
| Supply chain | Total cost of ownership, standardisation across facilities, supply reliability | A total cost model including consumables, service, disposal and training — built jointly rather than presented | Unit price alone, in either direction |
| Finance | Budget impact, capital versus operating treatment, payback period | A budget impact model in the institution's own financial terms, including what it displaces | Return on investment computed from vendor assumptions |
The practical implication is a sequencing one. A committee submission built only on clinical evidence answers one member's question and leaves three unanswered, and the three unanswered ones control the budget. The strongest submissions are assembled with supply chain and finance rather than presented to them — which takes longer, requires access most commercial teams do not have, and is the reason account relationships in medtech are worth what they are.
The rep-less question, with the arithmetic
Few debates in medtech commercial strategy generate more heat and less arithmetic. It deserves a numerical answer because a numerical claim started it.
The argument runs as follows. Hospital networks, having taken purchasing control from individual physicians, observed that a substantial share of a device's price was the manufacturer's selling cost. Some networks argued that vendor selling, general and administrative cost reached up to 40% of the implant price. If the representative could be removed and the hospital take on the associated tasks, that cost could be negotiated away.
The arithmetic in the worked example used to support the argument does not reach 40%. A representative costing $375,000 a year, serving a territory in which a given hospital represents 10% of volume, is attributable to that hospital at roughly $37,500. Against a $1 million account, that is approximately 3.75% — an order of magnitude below the headline claim. The 40% figure describes total company SG&A, which includes marketing, administration, regulatory and management. Very little of it is negotiable by removing one representative from one hospital.
| What the rep does | What happens if the rep is removed | Who pays for it then |
|---|---|---|
| Case support in theatre | The task does not disappear. Someone must know the instrument set | The hospital hires technicians or buys third-party case support |
| Training on new devices and staff turnover | Becomes the hospital's continuing obligation | Hospital education budget, indefinitely |
| Stocking, consignment and expiry management | Transfers to hospital supply chain | Hospital working capital, which was previously the vendor's |
| Sterilisation coordination and instrument logistics | Transfers to sterile services | Hospital operations |
| Product issue escalation and troubleshooting | Slower, through a support channel rather than a person present | Paid in theatre time, which is the most expensive hour in the building |
Reported adopters exist and reported savings are real — Mercy Hospital Springfield in spine and Loma Linda University Medical Center in orthopaedic implants are the examples usually named, and both are reported to have cut device spend materially. The honest conclusion is narrower than either side's version: the rep-less model works where the procedure is standardised, the instrument set is stable and volume is high enough to justify in-house expertise. It works poorly where technique varies, technology changes frequently or volume is low — because there the transferred cost exceeds the negotiated saving, and the transfer is invisible until it has happened.
What a device company should take from this
Do not defend the representative on the basis of the relationship. That argument loses to a spreadsheet, and it should.
Defend it, or price it, on the basis of the transferred cost. The tasks are enumerable — case support, training, stocking, sterilisation coordination, escalation — and each has a cost the hospital will incur if the vendor stops performing it. A commercial team that can put a credible number against each is negotiating about the same thing procurement is.
The strategic version of this is to unbundle deliberately rather than defensively. Offering a supported price and an unsupported price, with the difference explicit, converts a losing argument about value into a pricing menu — and in standardised, high-volume categories the unsupported option is one the customer was going to build anyway.
The regulatory calendar is now a commercial constraint
For most of the last decade, regulatory affairs and commercial strategy in medtech were separate conversations. Under MDR and IVDR they are the same conversation, because the cost of keeping a SKU on the market has risen enough to make portfolio breadth a commercial decision.
| Requirement | Deadline | Applies to | Commercial consequence |
|---|---|---|---|
| EU MDR full compliance | 31 December 2027 | High-risk class III devices and certain class IIb implantable devices | The near deadline. Products without a credible notified body path need a decision now, not a renewal plan |
| EU MDR full compliance | 31 December 2028 | Remaining class IIb, and class IIa, Im, Is and Ir devices | The volume deadline — where most SKUs sit, and where rationalisation decisions concentrate |
| Extension conditions | Continuous | Both of the above | Extensions are conditional on market surveillance, quality management systems and notified body engagement. They are not automatic |
| EU IVDR | 26 May 2025 (passed) for high-risk; 26 May 2027 to 26 May 2028 for medium and lower risk | In vitro diagnostics by class | Diagnostics portfolios face the same rationalisation logic on a slightly different clock |
| EU AI Act, embedded high-risk AI | 2 August 2028, moved from 2 August 2027 | AI within regulated products, including medical devices | Deferred under the agreed Digital Omnibus, provisional pending Official Journal publication. Verify status before relying on it |
| India BIS Scheme X certification | 1 September 2026 | Devices within the notified BIS scope | The nearest hard deadline for the Indian market. Non-certification means loss of market access |
Notified body capacity is the constraint that turns a compliance question into a commercial one. When the MDR transition was first extended, only a few dozen notified bodies were designated against many thousands of manufacturers, and while capacity has grown, the queue rather than the requirement is what determines whether a given SKU makes its date. The commercial response is unglamorous and consequential: rank the portfolio by contribution, secure the top of it early, and decide deliberately which tail products to discontinue rather than discovering the answer through a missed deadline.
India: what is structurally different
Two corrections and one deadline, because the Indian device environment is frequently described inaccurately in material written elsewhere.
| Point | The position | Commercial implication |
|---|---|---|
| Devices are not regulated as drugs | They sit under the Medical Devices Rules, 2017 — a separate framework. The persistent description of Indian devices as regulated under drug law is inaccurate | Registration strategy, documentation and timelines follow the device framework. Planning against drug-regulation assumptions produces the wrong schedule |
| Risk classification and authority | Class A and B are licensed by state authorities, typically in about 3–6 months. Class C and D are licensed centrally by CDSCO, typically in about 6–12 months | Classification decides both the timeline and who you deal with. A misclassification is a lost year, not a lost form |
| Software as a medical device | A draft guidance issued in October 2025 establishes the first formal framework, distinguishing standalone software from embedded firmware and requiring algorithm change protocols and cybersecurity risk assessment for AI and machine learning systems | Indicative timelines of roughly 90–120 days for Class C and 120–180 days for Class D software. A real route to market where previously there was ambiguity |
| BIS Scheme X certification | Deadline extended to 1 September 2026 for devices within the notified scope | The nearest hard commercial deadline in the Indian market. Missing it removes market access rather than delaying it |
The commercial reading for a device company operating in India is that the model choice tilts towards subscription and service more strongly than in the United States or Europe, for a structural reason rather than a fashionable one: a large share of the private hospital market is capital-constrained while being operationally cash-generative. A buyer who cannot approve a capital purchase can frequently approve a monthly operating cost — which makes model four the practical route into accounts that a capital sale cannot reach at all.
A worked example: choosing a model for one product
The models only become a decision when applied to a specific product and buyer. The following works through an illustrative case — a mid-priced diagnostic instrument with a proprietary reagent, sold to mid-size private hospitals. The figures demonstrate the method rather than report a real product.
| Test | Finding in this example | What it rules in or out |
|---|---|---|
| Does the buyer have capital budget? | Rarely. Capital approval requires a board cycle and competes with clinical expansion | Rules out a pure capital sale as the primary route, though it remains viable for the largest accounts |
| Is there a genuine recurring consumable? | Yes — a proprietary reagent, with a credible third-party substitute emerging in two years | Rules in capital-plus-consumables, with a stated expiry on the assumption. The substitution risk must be modelled, not ignored |
| Does downtime carry a cost the buyer already feels? | Yes. An instrument out of service diverts tests to an external laboratory at a known price | Rules in a service and uptime agreement, and gives it a value the buyer can compute themselves |
| Can we own the asset on our balance sheet? | For up to roughly 40 placements before working capital becomes binding | Rules device-as-a-service in, but caps it. A subscription strategy without a placement ceiling is a financing plan, not a commercial one |
| Is there a measurable, attributable outcome? | Turnaround time is measurable; clinical outcome is not attributable to the instrument alone | Rules out outcome-based contracting on clinical grounds and rules it in on operational ones — a narrower but executable version |
| Can the buyer's procurement execute a subscription? | Two of five target accounts can; three cannot without a policy change | The decisive constraint, and the one usually discovered last. It determines the addressable market for the model far more than appetite does |
The conclusion this example produces
Not one model — two, deliberately, with a rule for which applies where.
Capital plus consumables and an uptime service agreement for accounts with capital access and high volume, where the consumable annuity is strongest and the substitution risk is managed by contract length rather than by hope.
Device as a service, capped at the placement ceiling, for capital-constrained accounts whose procurement can execute it — which the assessment shows is two of five target accounts, not all of them.
The operational-outcome variant, on turnaround time, held in reserve as a competitive response rather than a launch position, because it is credible and the clinical version is not.
The discipline that produces this is the last test in the table. Most model strategies fail because nobody asked whether the customer's purchasing process can buy the thing being proposed — and that question costs one meeting.
Where device commercial strategies fail
- Importing a pharmaceutical playbook. The buyer is a committee, not a prescriber, and the service is part of the product rather than part of the selling cost. Both differences are structural and neither is fixed by better execution.
- Submitting clinical evidence to a four-part committee. Clinicians are one of four constituencies in the room, and the other three control the budget. A submission without a total cost model and a budget impact model answers a quarter of the question.
- Proposing outcome-based contracts to buyers who cannot purchase them. Every published source names procurement frameworks as the barrier. Test whether the buyer's process can execute the model before designing a commercial strategy around it.
- Defending the representative on relationship value. It loses to a spreadsheet. The defensible version is the transferred cost — case support, training, stocking, sterilisation coordination and escalation, each with a number attached.
- Treating the models as a maturity ladder. Moving to a subscription is not progress; it is a different business with different working capital needs, revenue recognition and field responsibilities. The strategy usually survives; the cost base does not.
- Running a subscription strategy without a placement ceiling. Every placement consumes balance sheet. A model with no cap is a financing decision that has not been taken deliberately.
- Treating the regulatory calendar as an affairs problem. With MDR compliance landing on 31 December 2027 and 31 December 2028 and notified body capacity as the binding constraint, portfolio rationalisation is a commercial decision that will otherwise be made for you by a missed queue position.
A sequence for setting device commercial strategy
Ordered so that the constraints are established before the model is chosen, because the constraints eliminate more options than the ambitions create.
- Establish the buyer's budget reality first. Capital availability, operating budget flexibility, and — critically — whether procurement can execute a subscription or an outcome-based agreement at all. This is answerable in one meeting per account type and it eliminates models before any modelling effort is spent on them.
- Map the value analysis committee for your top accounts. Who sits on it, what evidence each constituency needs, whether it decides centrally or per facility, and when the relevant category is reviewed. The review date reorders the commercial calendar more than any other single fact.
- Cost the service honestly, then decide whether to bundle it. Enumerate what the field organisation actually delivers and what each element costs. This is the input to both the pricing decision and the rep-less conversation, and most organisations have never assembled it.
- Rank the portfolio against the regulatory calendar. Contribution against MDR and IVDR dates and notified body queue position. Decide deliberately which tail SKUs to discontinue, and free the regulatory capacity for the products that carry the business.
- Choose the model per segment, not per company, and set the ceiling. Different buyer types justify different models, and a subscription element needs an explicit placement cap tied to working capital. Write down the assumption that would make you change model — consumable substitution, procurement policy change, a competitor's unsupported price — so the review is triggered by evidence rather than by a bad quarter.
One expectation to set. Steps one and four routinely reduce the addressable strategy rather than expand it, which makes them unpopular to present and valuable to complete. A model strategy built without them is a description of what the company would like to sell, rather than of what this market can buy.
Key takeaways
The seven actions this article argues for, separated from the evidence that supports them.
- Establish the buyer's budget reality first. Capital availability, operating budget flexibility, and above all whether procurement can execute a subscription or an outcome-based agreement at all.
- Test the procurement process before designing around a model. Every published source names procurement frameworks as the barrier to outcome-based contracting, and that question is answerable in one meeting.
- Assemble the value analysis submission with supply chain and finance, not for them. A clinical dossier answers one of the four constituencies in the room and the other three control the budget.
- Defend the representative on transferred cost, not on relationship value. Case support, training, stocking, sterilisation and escalation each carry a number the hospital will pay if you stop performing them.
- Set an explicit placement ceiling on any subscription element. Every placement consumes balance sheet, and a model without a cap is an untaken financing decision.
- Rank the portfolio against the regulatory calendar and decide which tail SKUs to discontinue. With MDR compliance landing on 31 December 2027 and 31 December 2028, the queue rather than the requirement decides what survives.
- Choose the model per segment and write down what would change it — consumable substitution, a procurement policy change, a competitor's unsupported price — so the review is triggered by evidence rather than by a poor quarter.
Conclusion
Medical device commercial strategy is usually discussed as a pricing question and is actually an operating model question. Moving from a capital sale to a subscription changes who owns the asset, who maintains it, how revenue is recognised, how much working capital is committed and what the field organisation does all day. That is why model changes in medtech fail at implementation rather than at strategy — the strategy is usually sound, and the organisation was costed for the model it is leaving.
The evidence on the newer models deserves to be reported as it is rather than as the category would like. Outcome-based contracting and device-as-a-service are real, documented and rare, with a small number of named programmes concentrated in one manufacturer's portfolio and a flagship value-based procurement case that began in 2016. They are worth pursuing where the conditions hold. They are not yet a category in rapid adoption, and a commercial plan built on the assumption that they are will be waiting on buyers whose procurement functions cannot execute them.
Four questions decide the model, and the fourth eliminates more strategies than the first three combined. Does the buyer have capital or only operating budget? Is there a defensible recurring consumable? Can we carry the asset, and up to how many placements? And can this customer's procurement actually buy what we are proposing? That last one is almost always asked last, and it should be asked first.
Frequently Asked Questions For Medical Device Commercial Strategy
It is the decision about how a device earns revenue, and it is structural rather than a matter of pricing. Five models are available: an outright capital sale; capital plus proprietary consumables; capital plus a service and uptime agreement; device as a service on subscription; and outcome-based contracting where payment depends on a clinical or economic result. The right choice follows from three constraints — whether the buyer has capital budget or only operating budget, whether the product carries a defensible recurring consumable, and whether an outcome exists that is measurable and attributable. The choice sets cash profile, sales structure and evidence burden simultaneously, which is why it cannot be varied deal by deal.
A model in which the customer pays a periodic subscription covering the equipment, its service, consumables and often software, rather than buying the device outright. It suits buyers who are capital-constrained but cash-generative, which describes much of the mid-size private hospital market in India and other emerging markets. The main constraints are on the manufacturer's side: every placement consumes balance sheet, so a subscription strategy needs an explicit placement ceiling tied to working capital, and revenue recognition and asset ownership both change. The second constraint is on the buyer's side and is more often decisive — many procurement functions are built to buy products at prices and cannot execute a subscription without a policy change.
They are documented, and they are rare. Published examples include Medtronic's TYRX antibacterial envelope, where the manufacturer reimburses hospitals for costs associated with device infections; Cardiva Medical's VASCADE, covering post-surgical complication costs when targets are not met; Medtronic's MiniMed agreement with Aetna, tying payment to HbA1c targets and total cost of care; and Medtronic's Catalonia ICD programme, which reported roughly 10% reductions in outpatient visits and implant complications within a €10 million four-year budget. Two honest observations: the examples concentrate heavily in one manufacturer's portfolio, and the most-cited value-based procurement case dates from 2016. Every source names the same barrier — procurement frameworks that cannot buy outcomes over periods — so test the buyer's process before designing around the model.
Through a value analysis committee assessing the institution's interest rather than an individual clinician expressing a preference. Four constituencies sit in the room and each asks a different question: clinicians on efficacy, safety and capability; nursing and theatre staff on workflow and training burden; supply chain on total cost of ownership, standardisation and supply reliability; and finance on budget impact, capital versus operating treatment and payback. A submission built only on clinical evidence answers one of the four, and the other three control the budget. The strongest submissions are assembled jointly with supply chain and finance rather than presented to them, which takes longer and is a large part of what an account relationship in medtech is actually for.
It is real in specific conditions and oversold in general. The claim that started the debate was that vendor selling, general and administrative cost reached up to 40% of implant price. The arithmetic in the worked example used to support it does not reach that: a representative costing $375,000 a year, in a territory where one hospital is 10% of volume, is attributable to a $1 million account at roughly $37,500 — about 3.75%. The 40% figure describes total company SG&A, most of which is not negotiable by removing one representative. Reported adopters do exist and have cut device spend materially, notably in spine and orthopaedic implants. The honest boundary is that the model works where procedures are standardised, instrument sets are stable and volume justifies in-house expertise — because the case support, training, stocking and sterilisation work does not disappear, it transfers, and it has a cost.
Full MDR compliance is required by 31 December 2027 for high-risk class III devices and certain class IIb implantable devices, and by 31 December 2028 for remaining class IIb devices along with class IIa, Im, Is and Ir. The extensions are conditional — on market surveillance, quality management systems and engagement with notified bodies — rather than automatic. For in vitro diagnostics under IVDR, high-risk devices transitioned by 26 May 2025, with medium and lower-risk categories falling between 26 May 2027 and 26 May 2028. Separately, AI embedded in regulated products including medical devices moved to 2 August 2028 under the agreed EU Digital Omnibus, from 2 August 2027; that agreement was provisional and awaiting Official Journal publication at the time of writing, so its status should be verified.
Under the Medical Devices Rules, 2017 — not as drugs, despite a persistent description to the contrary in material written outside India. Devices fall into four risk classes: Class A and Class B are licensed by state authorities, typically in about three to six months, while Class C and Class D are licensed centrally by CDSCO, typically in about six to twelve months. A draft guidance issued in October 2025 established the first formal framework for software as a medical device, distinguishing standalone software from embedded firmware and requiring algorithm change protocols and cybersecurity risk assessment for AI and machine learning systems, with indicative timelines of roughly 90–120 days for Class C and 120–180 days for Class D. The nearest hard commercial deadline is BIS Scheme X certification, extended to 1 September 2026 for devices within the notified scope.
Usually two, applied by segment, rather than one applied everywhere. The choice follows from four tests: whether the buyer has capital budget, whether a defensible recurring consumable exists, whether downtime carries a cost the buyer already feels, and whether the buyer's procurement function can actually execute the model being proposed — the last being the constraint most often discovered last and the one that determines the addressable market. Where a subscription element is used it needs an explicit placement ceiling tied to working capital, because each placement consumes balance sheet. Write down in advance the assumption that would trigger a change of model — consumable substitution, a procurement policy change, a competitor's unsupported price — so the review happens on evidence rather than after a poor quarter.
Let's Discuss Your Requirements
